Hi JR Ewing. Welcome to the spotlight and don't se
Post# of 147789
(Total Views: 696)
Posted On: 01/30/2022 12:58:03 PM
Hi JR Ewing. Welcome to the spotlight and don't sell yourself short. You may very well become one of the best posters here. Back when I first started posting regularly I certainly didn't think I'd be awarded both 2020 & 2021 poster of the year, but here we are. The people have spoken, and they chose wisely if I’m being honest. But enough about me.
Let's answer your questions.
If Leronlimab wasn't a viable candidate for the various conditions it's in trials for the FDA wouldn't have approved those trials, and certainly wouldn't have approved follow up trials which are based on those initial trials showing signals of success. Many a drug is willingly pulled from drug trials because efficacy is non-existent or the safety issues overwhelm whatever possible efficacy exists. Notwithstanding Aduhelm and Remdesivir, the cream typically rises to the top and the chaff gets separated from the wheat well before anyone is allowed to make a pancake.
(Bonus points to anyone who knows the kids book that wheat/pancake comment derives from)
Another strong signal that Cytodyn has something in LL is just how dedicated the bashers are in their efforts to discredit and derail the success of Leronlimab. Nobody wastes that much time, effort, and money, on something that isn't worth it. It's been happening on every possible message board, relentlessly, for years now. And that's not even talking about the dbags working the same program from their "media" or "investor" companies like STAT.
To your second question, if the SEC was after Cytodyn and/or Nader we'd have heard about it. Though I’m no expert on the matter. I do think we wouldn’t have seen everyone stick around, especially the expert in SEC regulations who took on the chairman of the board role, had there been some major malfeasance on the part of Nader and/or the board. And especially if there wasn’t any promise in Leronlimab’s ability to perform. If it were a toxic environment, or the drug didn’t work, or there were some seriously illegal things going on the board would know and people would be fleeing en masse.
Now we’ll just need a follow up post to know which supercar you’ll buy once Cytodyn hits its first dinger, and whether you’re on Team Pie or Team Cake.
- Daytime Respert
Let's answer your questions.
If Leronlimab wasn't a viable candidate for the various conditions it's in trials for the FDA wouldn't have approved those trials, and certainly wouldn't have approved follow up trials which are based on those initial trials showing signals of success. Many a drug is willingly pulled from drug trials because efficacy is non-existent or the safety issues overwhelm whatever possible efficacy exists. Notwithstanding Aduhelm and Remdesivir, the cream typically rises to the top and the chaff gets separated from the wheat well before anyone is allowed to make a pancake.
(Bonus points to anyone who knows the kids book that wheat/pancake comment derives from)
Another strong signal that Cytodyn has something in LL is just how dedicated the bashers are in their efforts to discredit and derail the success of Leronlimab. Nobody wastes that much time, effort, and money, on something that isn't worth it. It's been happening on every possible message board, relentlessly, for years now. And that's not even talking about the dbags working the same program from their "media" or "investor" companies like STAT.
To your second question, if the SEC was after Cytodyn and/or Nader we'd have heard about it. Though I’m no expert on the matter. I do think we wouldn’t have seen everyone stick around, especially the expert in SEC regulations who took on the chairman of the board role, had there been some major malfeasance on the part of Nader and/or the board. And especially if there wasn’t any promise in Leronlimab’s ability to perform. If it were a toxic environment, or the drug didn’t work, or there were some seriously illegal things going on the board would know and people would be fleeing en masse.
Now we’ll just need a follow up post to know which supercar you’ll buy once Cytodyn hits its first dinger, and whether you’re on Team Pie or Team Cake.
- Daytime Respert
(15)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼